Parsec Financial Management Inc. boosted its stake in Pfizer, Inc. (NYSE:PFE) by 1.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,195 shares of the biopharmaceutical company’s stock after buying an additional 257 shares during the period. Parsec Financial Management Inc.’s holdings in Pfizer were worth $481,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. River & Mercantile Asset Management LLP increased its stake in Pfizer by 82.0% in the second quarter. River & Mercantile Asset Management LLP now owns 198,706 shares of the biopharmaceutical company’s stock valued at $6,995,000 after buying an additional 89,500 shares during the period. Warren Averett Asset Management LLC increased its stake in Pfizer by 3.1% in the second quarter. Warren Averett Asset Management LLC now owns 7,411 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 221 shares during the period. City Holding Co. increased its stake in Pfizer by 7.3% in the second quarter. City Holding Co. now owns 53,084 shares of the biopharmaceutical company’s stock valued at $1,869,000 after buying an additional 3,634 shares during the period. Douglass Winthrop Advisors LLC increased its stake in Pfizer by 47.2% in the second quarter. Douglass Winthrop Advisors LLC now owns 79,600 shares of the biopharmaceutical company’s stock valued at $2,500,000 after buying an additional 25,538 shares during the period. Finally, Gofen & Glossberg LLC IL increased its stake in Pfizer by 0.9% in the second quarter. Gofen & Glossberg LLC IL now owns 505,144 shares of the biopharmaceutical company’s stock valued at $17,786,000 after buying an additional 4,392 shares during the period. 68.39% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.25% during trading on Friday, hitting $32.52. The stock had a trading volume of 20,291,186 shares. The stock has a market capitalization of $197.34 billion, a P/E ratio of 32.65 and a beta of 0.91. The stock’s 50-day moving average is $32.41 and its 200-day moving average is $33.71. Pfizer, Inc. has a 12-month low of $28.25 and a 12-month high of $37.39.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $0.61 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.62 by $0.01. Pfizer had a net margin of 13.09% and a return on equity of 23.68%. The firm earned $13.05 billion during the quarter, compared to the consensus estimate of $13.05 billion. During the same period in the previous year, the business earned $0.60 earnings per share. The firm’s revenue for the quarter was up 7.9% on a year-over-year basis. Analysts predict that Pfizer, Inc. will post $2.42 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 1st. Shareholders of record on Friday, February 3rd will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.94%. This is an increase from Pfizer’s previous quarterly dividend of $0.30. The ex-dividend date of this dividend is Wednesday, February 1st. Pfizer’s dividend payout ratio (DPR) is presently 106.20%.

WARNING: “Parsec Financial Management Inc. Boosts Stake in Pfizer, Inc. (PFE)” was reported by Daily Political and is the propert of of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at http://www.dailypolitical.com/2017/01/13/parsec-financial-management-inc-boosts-stake-in-pfizer-inc-pfe.html.

PFE has been the subject of several recent analyst reports. Atlantic Securities set a $35.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Thursday, November 3rd. Sanford C. Bernstein set a $36.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, November 1st. Argus reiterated a “buy” rating and set a $39.00 price target on shares of Pfizer in a research note on Tuesday, October 4th. Bank of America reiterated a “buy” rating and set a $40.00 price target on shares of Pfizer in a research note on Tuesday, September 27th. Finally, Vetr downgraded Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.36 price target for the company. in a research note on Thursday, October 13th. Twelve analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $37.30.

In other Pfizer news, insider Anthony J. Maddaluna sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total value of $330,000.00. Following the completion of the transaction, the insider now directly owns 112,087 shares of the company’s stock, valued at approximately $3,698,871. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Albert Bourla sold 18,390 shares of the firm’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $30.05, for a total transaction of $552,619.50. Following the completion of the transaction, the insider now directly owns 149,199 shares of the company’s stock, valued at $4,483,429.95. The disclosure for this sale can be found here. 0.07% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.

5 Day Chart for NYSE:PFE

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.